Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 444


Pneumoproteins KL-6 and CCL-18 Predict Progression of Interstitial Lung Disease in Systemic Sclerosis.

Volkmann ER, Tashkin DP, Kuwana M, Li N, Roth MD, Charles J, Hant FN, Bogatkevich GS, Akter T, Kim G, Goldin J, Khanna D, Clements PJ, Furst DE, Elashoff RM, Silver RM, Assassi S.

Arthritis Rheumatol. 2019 Jun 24. doi: 10.1002/art.41020. [Epub ahead of print]


Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: a European Scleroderma Trials and Research (EUSTAR) analysis.

Becker M, Graf N, Sauter R, Allanore Y, Curram J, Denton CP, Khanna D, Matucci-Cerinic M, de Oliveira Pena J, Pope JE, Distler O; EUSTAR Collaborators; EUSTAR Collaborators (numerical order of centres).

Ann Rheum Dis. 2019 Jun 21. pii: annrheumdis-2019-215145. doi: 10.1136/annrheumdis-2019-215145. [Epub ahead of print]


Knowledge, attitude, and practice about cervical cancer and its screening among community healthcare workers of Varanasi district, Uttar Pradesh, India.

Khanna D, Khargekar N, Budukh A.

J Family Med Prim Care. 2019 May;8(5):1715-1719. doi: 10.4103/jfmpc.jfmpc_143_19.


Impact of the Revised Hemodynamic Definition on the Diagnosis of Pulmonary Hypertension in Patients with Systemic Sclerosis.

Jaafar S, Visovatti S, Young A, Huang S, Cronin P, Vummidi D, McLaughlin V, Khanna D.

Eur Respir J. 2019 Jun 13. pii: 1900586. doi: 10.1183/13993003.00586-2019. [Epub ahead of print]


Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study.

Kwakkenbos L, Thombs BD, Khanna D, Carrier ME, Baron M, Furst DE, Gottesman K, van den Hoogen F, Malcarne VL, Mayes MD, Mouthon L, Nielson WR, Poiraudeau S, Riggs R, Sauvé M, Wigley F, Hudson M, Bartlett SJ.

Rheumatology (Oxford). 2019 Jun 5. pii: kez234. doi: 10.1093/rheumatology/kez234. [Epub ahead of print] No abstract available.


Setting the international standard for longitudinal follow-up of patients with systemic sclerosis: a Delphi-based expert consensus on core clinical features.

Hoffmann-Vold AM, Distler O, Murray B, Kowal-Bielecka O, Khanna D, Allanore Y; EUSTAR and SCTC collaborators.

RMD Open. 2019 Mar 4;5(1):e000826. doi: 10.1136/rmdopen-2018-000826. eCollection 2019.


Health and Hygienic Parameters of Food Handlers and Sanitary Status of Food Establishments in a Medical College of Delhi.

Khanna D, Banerjee B, Tomar A, Gupta K, Pangtey R, Garg S.

Indian J Community Med. 2019 Jan-Mar;44(1):66-67. doi: 10.4103/ijcm.IJCM_248_18. No abstract available.


5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma.

Kahl DJ, Hutchings KM, Lisabeth EM, Haak AJ, Leipprandt JR, Dexheimer T, Khanna D, Tsou PS, Campbell PL, Fox DA, Wen B, Sun D, Bailie M, Neubig RR, Larsen SD.

J Med Chem. 2019 May 9;62(9):4350-4369. doi: 10.1021/acs.jmedchem.8b01772. Epub 2019 Apr 18.


An Interim Report of the Scleroderma Clinical Trials Consortium Working Groups.

Baron M, Kahaleh B, Bernstein EJ, Chung L, Clements PJ, Denton C, Domsic RT, Ferdowsi N, Foeldvari I, Frech T, Gordon JK, Hudson M, Johnson SR, Khanna D, McMahan Z, Merkel PA, Narain S, Nikpour M, Pauling JD, Ross L, Valenzuela Vergara AM, Vacca A.

J Scleroderma Relat Disord. 2019 Feb;4(1):17-27. doi: 10.1177/2397198318783926. Epub 2018 Jul 18.


Identification of Cysteine-Rich Angiogenic Inducer 61 as a Potential Antifibrotic and Proangiogenic Mediator in Scleroderma.

Tsou PS, Khanna D, Sawalha AH.

Arthritis Rheumatol. 2019 Mar 18. doi: 10.1002/art.40890. [Epub ahead of print]


Management of systemic sclerosis-associated interstitial lung disease.

Roofeh D, Jaafar S, Vummidi D, Khanna D.

Curr Opin Rheumatol. 2019 May;31(3):241-249. doi: 10.1097/BOR.0000000000000592.


Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.

Wu W, Jordan S, Graf N, de Oliveira Pena J, Curram J, Allanore Y, Matucci-Cerinic M, Pope JE, Denton CP, Khanna D, Distler O; EUSTAR Collaborators.

Ann Rheum Dis. 2019 May;78(5):648-656. doi: 10.1136/annrheumdis-2018-213455. Epub 2019 Mar 9.


Evaluation of Scleroderma Clinical Trials Consortium training recommendations on modified Rodnan skin score assessment in scleroderma.

Low AHL, Ng SA, Berrocal V, Brennan B, Chan G, Ng SC, Khanna D.

Int J Rheum Dis. 2019 Jun;22(6):1036-1040. doi: 10.1111/1756-185X.13523. Epub 2019 Mar 6.


Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.

Volkmann ER, Tashkin DP, Sim M, Li N, Khanna D, Roth MD, Clements PJ, Hoffmann-Vold AM, Furst DE, Kim G, Goldin J, Elashoff RM.

J Rheumatol. 2019 Feb 15. pii: jrheum.180441. doi: 10.3899/jrheum.180441. [Epub ahead of print]


Prevalence, Treatment, and Outcomes of Coexistent Pulmonary Hypertension and Interstitial Lung Disease in Systemic Sclerosis.

Young A, Vummidi D, Visovatti S, Homer K, Wilhalme H, White ES, Flaherty K, McLaughlin V, Khanna D.

Arthritis Rheumatol. 2019 Feb 14. doi: 10.1002/art.40862. [Epub ahead of print]


Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma.

Tsou PS, Campbell P, Amin MA, Coit P, Miller S, Fox DA, Khanna D, Sawalha AH.

Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3695-3702. doi: 10.1073/pnas.1813006116. Epub 2019 Feb 12.


Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.

Pauling JD, Frech TM, Hughes M, Gordon JK, Domsic RT, Anderson ME, Ingegnoli F, McHugh NJ, Johnson SR, Hudson M, Boin F, Ong VH, Matucci-Cerinic M, Altorok N, Scolnik M, Nikpour M, Shah A, Pope JE, Khanna D, Herrick AL.

J Scleroderma Relat Disord. 2018 Oct;3(3):249-252. doi: 10.1177/2397198318774307. Epub 2018 May 24.


Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).

Khanna D, Clements PJ, Volkmann ER, Wilhalme H, Tseng CH, Furst DE, Roth MD, Distler O, Tashkin DP.

Arthritis Res Ther. 2019 Jan 16;21(1):23. doi: 10.1186/s13075-019-1809-y.


Study to Compare the Effect of Different Registration Methods on Patient Setup Uncertainties in Cone-beam Computed Tomography during Volumetric Modulated Arc Therapy for Breast Cancer Patients.

Mohandass P, Khanna D, Kumar TM, Thiyagaraj T, Saravanan C, Bhalla NK, Puri A.

J Med Phys. 2018 Oct-Dec;43(4):207-213. doi: 10.4103/jmp.JMP_67_18.


Efficacy and safety during extended treatment of lesinurad in combination with febuxostat in patients with tophaceous gout: CRYSTAL extension study.

Dalbeth N, Jones G, Terkeltaub R, Khanna D, Fung M, Baumgartner S, Perez-Ruiz F.

Arthritis Res Ther. 2019 Jan 7;21(1):8. doi: 10.1186/s13075-018-1788-4.


Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology.

Butler EA, Baron M, Fogo AB, Frech T, Ghossein C, Hachulla E, Hoa S, Johnson SR, Khanna D, Mouthon L, Nikpour M, Proudman S, Steen V, Stern E, Varga J, Denton C, Hudson M; Scleroderma Clinical Trials Consortium Scleroderma Renal Crisis Working Group.

Arthritis Rheumatol. 2019 Jun;71(6):964-971. doi: 10.1002/art.40809. Epub 2019 Apr 12.


Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities.

Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC.

QJM. 2019 Feb 1;112(2):81-93. doi: 10.1093/qjmed/hcy272. No abstract available.


Proceedings of the American College of Rheumatology/Association of Physicians of Great Britain and Ireland Connective Tissue Disease-Associated Interstitial Lung Disease Summit: A Multidisciplinary Approach to Address Challenges and Opportunities.

Fischer A, Strek ME, Cottin V, Dellaripa PF, Bernstein EJ, Brown KK, Danoff SK, Distler O, Hirani N, Jones KD, Khanna D, Lee JS, Lynch DA, Maher TM, Millar AB, Raghu G, Silver RM, Steen VD, Volkmann ER, Mullan RH, O'Dwyer DN, Donnelly SC.

Arthritis Rheumatol. 2019 Feb;71(2):182-195. doi: 10.1002/art.40769. Epub 2019 Jan 3. No abstract available.


Performance of Anti-Topoisomerase I Antibody Testing by Multiple-Bead, Enzyme-Linked Immunosorbent Assay and Immunodiffusion in a University Setting.

Homer KL, Warren J, Karayev D, Khanna PP, Young A, Nagaraja V, Metzger AL, Khanna D.

J Clin Rheumatol. 2018 Dec 20. doi: 10.1097/RHU.0000000000000971. [Epub ahead of print]


Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria.

Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD, Hahn BH, Hiepe F, Sánchez-Guerrero J, Massarotti E, Boumpas DT, Costenbader KH, Jayne D, Dörner T, Kamen DL, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Aringer M.

J Rheumatol. 2019 Jul;46(7):721-726. doi: 10.3899/jrheum.180478. Epub 2018 Dec 15.


Diagnosis of pulmonary hypertension.

Frost A, Badesch D, Gibbs JSR, Gopalan D, Khanna D, Manes A, Oudiz R, Satoh T, Torres F, Torbicki A.

Eur Respir J. 2019 Jan 24;53(1). pii: 1801904. doi: 10.1183/13993003.01904-2018. Print 2019 Jan.


Longitudinal Assessment of Patient-reported Outcome Measures in Systemic Sclerosis Patients with Gastroesophageal Reflux Disease - Scleroderma Clinical Trials Consortium.

McMahan ZH, Frech T, Berrocal V, Lim D, Bruni C, Matucci-Cerinic M, Smith V, Melsens K, Proudman S, Zhang J, Mendoza F, Woods M, Khanna D.

J Rheumatol. 2019 Jan;46(1):78-84. doi: 10.3899/jrheum.180004. Epub 2018 Nov 15.


Update of screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension.

Young A, Nagaraja V, Basilious M, Habib M, Townsend W, Gladue H, Badesch D, Gibbs JSR, Gopalan D, Manes A, Oudiz R, Satoh T, Torbicki A, Torres F, McLaughlin V, Khanna D.

Semin Arthritis Rheum. 2019 Jun;48(6):1059-1067. doi: 10.1016/j.semarthrit.2018.10.010. Epub 2018 Oct 14.


Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.

Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-Elstein L, Pinckney A, Furst DE, Clements PJ, Khanna D, Steen V, Schraufnagel DE, Arami S, Hsu V, Roth MD, Elashoff RM, Sullivan KM; SLS I and SLS II study groups.

Ann Rheum Dis. 2019 Jan;78(1):122-130. doi: 10.1136/annrheumdis-2018-213708. Epub 2018 Nov 8.


Ensemble Technique for Prediction of T-cell Mycobacterium tuberculosis Epitopes.

Khanna D, Rana PS.

Interdiscip Sci. 2018 Nov 7. doi: 10.1007/s12539-018-0309-0. [Epub ahead of print]


Response to: 'Effectiveness and safety of tocilizumab for the treatment of refractory systemic sclerosis associated interstitial lung disease: a case series' by Narváez.

Khanna D, Jahreis A, Lin CJF.

Ann Rheum Dis. 2018 Oct 23. pii: annrheumdis-2018-214477. doi: 10.1136/annrheumdis-2018-214477. [Epub ahead of print] No abstract available.



Bernstein EJ, Khanna D, Lederer DJ.

Arthritis Rheumatol. 2019 Feb;71(2):327-328. doi: 10.1002/art.40762. Epub 2018 Dec 29. No abstract available.


Burden of Gastrointestinal Symptoms in the United States: Results of a Nationally Representative Survey of Over 71,000 Americans.

Almario CV, Ballal ML, Chey WD, Nordstrom C, Khanna D, Spiegel BMR.

Am J Gastroenterol. 2018 Nov;113(11):1701-1710. doi: 10.1038/s41395-018-0256-8. Epub 2018 Oct 15.


Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial.

Mantero JC, Kishore N, Ziemek J, Stifano G, Zammitti C, Khanna D, Gordon JK, Spiera R, Zhang Y, Simms RW, Lafyatis R.

Clin Exp Rheumatol. 2018 Jul-Aug;36 Suppl 113(4):146-149. Epub 2018 Sep 30.


Risk Factors for Mortality and Cardiopulmonary Hospitalization in Systemic Sclerosis Patients At Risk for Pulmonary Hypertension, in the PHAROS Registry.

Hsu VM, Chung L, Hummers LK, Shah A, Simms R, Bolster M, Hant FN, Silver RM, Fischer A, Hinchcliff ME, Varga J, Goldberg AZ, Derk CT, Schiopu E, Khanna D, Shapiro LS, Domsic RT, Medsger T, Mayes MD, Furst D, Csuka ME, Molitor JA, Saketkoo LA, Salazar CR, Steen VD.

J Rheumatol. 2019 Feb;46(2):176-183. doi: 10.3899/jrheum.180018. Epub 2018 Oct 1.


Longitudinal Changes in Quantitative Interstitial Lung Disease on Computed Tomography after Immunosuppression in the Scleroderma Lung Study II.

Goldin JG, Kim GHJ, Tseng CH, Volkmann E, Furst D, Clements P, Brown M, Roth M, Khanna D, Tashkin DP.

Ann Am Thorac Soc. 2018 Nov;15(11):1286-1295. doi: 10.1513/AnnalsATS.201802-079OC.


Validation of a Software Upgrade in a Monte Carlo Treatment Planning System by Comparison of Plans in Different Versions.

Mohandass P, Khanna D, Manigandan D, Bhalla NK, Puri A.

J Med Phys. 2018 Apr-Jun;43(2):93-99. doi: 10.4103/jmp.JMP_7_18.


NEDD9 targets COL3A1 to promote endothelial fibrosis and pulmonary arterial hypertension.

Samokhin AO, Stephens T, Wertheim BM, Wang RS, Vargas SO, Yung LM, Cao M, Brown M, Arons E, Dieffenbach PB, Fewell JG, Matar M, Bowman FP, Haley KJ, Alba GA, Marino SM, Kumar R, Rosas IO, Waxman AB, Oldham WM, Khanna D, Graham BB, Seo S, Gladyshev VN, Yu PB, Fredenburgh LE, Loscalzo J, Leopold JA, Maron BA.

Sci Transl Med. 2018 Jun 13;10(445). pii: eaap7294. doi: 10.1126/scitranslmed.aap7294.


Ongoing clinical trials and treatment options for patients with systemic sclerosis-associated interstitial lung disease.

Khanna D, Tashkin DP, Denton CP, Lubell MW, Vazquez-Mateo C, Wax S.

Rheumatology (Oxford). 2019 Apr 1;58(4):567-579. doi: 10.1093/rheumatology/key151.


Skin Gene Expression Is Prognostic for the Trajectory of Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis.

Stifano G, Sornasse T, Rice LM, Na L, Chen-Harris H, Khanna D, Jahreis A, Zhang Y, Siegel J, Lafyatis R.

Arthritis Rheumatol. 2018 Jun;70(6):912-919. doi: 10.1002/art.40455.


Therapeutic interleukin-6 blockade reverses transforming growth factor-beta pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis.

Denton CP, Ong VH, Xu S, Chen-Harris H, Modrusan Z, Lafyatis R, Khanna D, Jahreis A, Siegel J, Sornasse T.

Ann Rheum Dis. 2018 Sep;77(9):1362-1371. doi: 10.1136/annrheumdis-2018-213031. Epub 2018 May 31.


Methyl-CpG-binding protein 2 mediates antifibrotic effects in scleroderma fibroblasts.

He Y, Tsou PS, Khanna D, Sawalha AH.

Ann Rheum Dis. 2018 Aug;77(8):1208-1218. doi: 10.1136/annrheumdis-2018-213022. Epub 2018 May 14.


Randomized Controlled Trial to Evaluate an Internet-Based Self-Management Program in Systemic Sclerosis.

Khanna D, Serrano J, Berrocal VJ, Silver RM, Cuencas P, Newbill SL, Battyany J, Maxwell C, Alore M, Dyas L, Riggs R, Connolly K, Kellner S, Fisher JJ, Bush E, Sachdeva A, Evnin L, Raisch DW, Poole JL.

Arthritis Care Res (Hoboken). 2019 Mar;71(3):435-447. doi: 10.1002/acr.23595. Epub 2019 Feb 5.


Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight-Week Placebo-Controlled Study Followed by a Sixteen-Week Open-Label Extension Study.

Allanore Y, Distler O, Jagerschmidt A, Illiano S, Ledein L, Boitier E, Agueusop I, Denton CP, Khanna D.

Arthritis Rheumatol. 2018 Oct;70(10):1634-1643. doi: 10.1002/art.40547. Epub 2017 Nov 6.


Brief Report: Whole-Exome Sequencing to Identify Rare Variants and Gene Networks That Increase Susceptibility to Scleroderma in African Americans.

Gourh P, Remmers EF, Boyden SE, Alexander T, Morgan ND, Shah AA, Mayes MD, Doumatey A, Bentley AR, Shriner D, Domsic RT, Medsger TA Jr, Steen VD, Ramos PS, Silver RM, Korman B, Varga J, Schiopu E, Khanna D, Hsu V, Gordon JK, Saketkoo LA, Gladue H, Kron B, Criswell LA, Derk CT, Bridges SL Jr, Shanmugam VK, Kolstad KD, Chung L, Jan R, Bernstein EJ, Goldberg A, Trojanowski M, Kafaja S, Maksimowicz-McKinnon KM, Mullikin JC, Adeyemo A, Rotimi C, Boin F, Kastner DL, Wigley FM.

Arthritis Rheumatol. 2018 Oct;70(10):1654-1660. doi: 10.1002/art.40541. Epub 2018 Aug 29.


pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis.

Kafaja S, Valera I, Divekar AA, Saggar R, Abtin F, Furst DE, Khanna D, Singh RR.

JCI Insight. 2018 May 3;3(9). pii: 98380. doi: 10.1172/jci.insight.98380.


Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.

Ingegnoli F, Schioppo T, Allanore Y, Caporali R, Colaci M, Distler O, Furst DE, Hunzelmann N, Iannone F, Khanna D, Matucci-Cerinic M.

Semin Arthritis Rheum. 2019 Feb;48(4):686-693. doi: 10.1016/j.semarthrit.2018.03.019. Epub 2018 Apr 4.


Monoclonal Gammopathy-Associated Scleromyxedema Presenting as Leonine Facies.

Park AY, Lowe L, Khanna D.

Arthritis Rheumatol. 2018 Oct;70(10):1694. doi: 10.1002/art.40530. No abstract available.


The patient experience of Raynaud's phenomenon in systemic sclerosis.

Pauling JD, Saketkoo LA, Matucci-Cerinic M, Ingegnoli F, Khanna D.

Rheumatology (Oxford). 2019 Jan 1;58(1):18-26. doi: 10.1093/rheumatology/key026.


Multinational Qualitative Research Study Exploring the Patient Experience of Raynaud's Phenomenon in Systemic Sclerosis.

Pauling JD, Domsic RT, Saketkoo LA, Almeida C, Withey J, Jay H, Frech TM, Ingegnoli F, Dures E, Robson J, McHugh NJ, Herrick AL, Matucci-Cerinic M, Khanna D, Hewlett S.

Arthritis Care Res (Hoboken). 2018 Sep;70(9):1373-1384. doi: 10.1002/acr.23475. Epub 2018 Aug 16.

Supplemental Content

Loading ...
Support Center